Harvard Bioscience Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY Revenue (est.)
$89.8Mnext fiscal year
FY EPS (est.)
-$0.38next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Gross Margin Quarterly5,900.0%Target: 60+%
Annual Cost Savings from Project Viking Annually0.0Target: $3 million in 2027 and $4 million in 2028
Recurring Revenue Share Annually5,500.0%Target: Higher recurring revenue mix
Watch Items
- Project Viking Manufacturing ConsolidationTrigger: Phased closure of Holliston, MA plant and transition to Minneapolis, MNAction: Monitor transition-related operating expenses and potential order fulfillment disruptions through H1 2027
- New Product Innovation (NPI) Adoption RatesTrigger: Sales growth of MeshMEA, BTX Electroporation, and SoHo Telemetry systemsAction: Track biopharma sector penetration and impact on gross margin expansion
Research as of 20 Jun 2026